lystn

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

• Moving beyond lipid lowering to address residual inflammatory risk
• Novel anti-inflammatory targets for ASCVD 

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD 
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD